Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021)
Johnson & Johnson's (JNJ) quarterly Construction in Progress came in at $4.3 billion in Q1 2021, up 18.67% year-over-year from $3.6 billion in Q1 2020, and up 18.67% quarter-over-quarter from $3.6 billion in Q4 2019.
Analysis
Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021) Analysis & Trends
Johnson & Johnson has disclosed Construction in Progress across 10 years of filings, most recently posting $4.3 billion for Q1 2021.
- In Q1 2021, Construction in Progress rose 18.67% year-over-year to $4.3 billion; the TTM figure through Jan 2021 stood at $4.3 billion (up 18.67% YoY), while the FY2021 annual figure was $4.3 billion, up 18.67% from the prior year.
- Construction in Progress came in at $4.3 billion for Q1 2021 at Johnson & Johnson, up from $3.6 billion in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $4.3 billion in Q1 2021 to a low of $3.4 billion in Q1 2017.
- Average Construction in Progress over 4 years is $3.7 billion, with a median of $3.6 billion recorded in 2019.
- Year-over-year, Construction in Progress dropped 6.17% in 2019 and gained 18.67% in 2021.
- Over 4 years, Construction in Progress stood at $3.4 billion in 2017, then gained by 12.41% to $3.9 billion in 2018, then retreated by 6.17% to $3.6 billion in 2019, then advanced by 18.67% to $4.3 billion in 2021.
- Per Business Quant data, the three most recent Construction in Progress figures were $4.3 billion in Q1 2021, $3.6 billion in Q4 2019, and $3.9 billion in Q4 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn | - |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn | - |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn | - |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jan 3, 2021 | 4.32 Bn |
| Dec 29, 2019 | 3.64 Bn |
| Dec 30, 2018 | 3.88 Bn |
| Dec 31, 2017 | 3.45 Bn |
| Jan 1, 2017 | 3.35 Bn |
| Jan 3, 2016 | 3.53 Bn |
| Dec 28, 2014 | 3.60 Bn |
| Dec 29, 2013 | 3.30 Bn |
| Dec 30, 2012 | 2.74 Bn |
| Jan 1, 2012 | 2.50 Bn |
| Jan 2, 2011 | 2.58 Bn |
| Jan 3, 2010 | 2.52 Bn |